Nancy Saravia, PhD, MSc
Professor Adjunct of Epidemiology (Microbial Diseases)About
Research
Publications
2025
Unlocking the power of implementation research
Penkunas M, Dako-Gyeke P, Saravia N, Mahendradhata Y, Faye A, Rampal S, Sarymsakova B, Rebai W, Reeder J, Vahedi M, Thorson A. Unlocking the power of implementation research. BMC Global And Public Health 2025, 3: 112. PMID: 41373057, PMCID: PMC12696911, DOI: 10.1186/s44263-025-00171-9.Peer-Reviewed Original ResearchInterplay of human macrophage response and natural resistance of infection by L. (V.) panamensis to pentavalent antimony
Fernández O, Belew A, Rosales-Chilama M, Sánchez-Hidalgo A, Colmenares M, Saravia N, El-Sayed N. Interplay of human macrophage response and natural resistance of infection by L. (V.) panamensis to pentavalent antimony. PLOS Neglected Tropical Diseases 2025, 19: e0013600. PMID: 41052143, PMCID: PMC12517518, DOI: 10.1371/journal.pntd.0013600.Peer-Reviewed Original ResearchConceptsNatural resistancePrincipal host cellsModulatory effectsInfected monocyte-derived macrophagesElevated expressionOutcome of Leishmania infectionResponse to treatmentAntimonial drugsActivation of macrophagesHost response mechanismsMonocyte-derived macrophagesDownregulation of transportersResistance of infectionHuman macrophage responsesHealthy donorsClinical strainsDrug resistanceParasite-host interactionsTranscriptome analysisLeishmania sppLeishmania infectionMacrophage responseMacrophagesMicrobicidal responsesInfection
2024
Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis
Fernández O, Rosales-Chilama M, Sánchez-Hidalgo A, Gómez P, Rebellón-Sánchez D, Regli I, Díaz-Varela M, Tacchini-Cottier F, Saravia N. Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis. PLOS Neglected Tropical Diseases 2024, 18: e0012156. PMID: 38709850, PMCID: PMC11098511, DOI: 10.1371/journal.pntd.0012156.Peer-Reviewed Original ResearchConceptsAssociated with treatment failureTreatment failureHost risk factorsBALB/c miceRisk factorsDrug susceptibilityClinical strainsOutcome of cutaneous leishmaniasisOdds of treatment failureMeglumine antimoniateParasitological response to treatmentLeishmania (Viannia) panamensisSubgroup of patientsAntimicrobial drug susceptibilityResponse to treatmentU937 macrophagesEvaluate drug susceptibilityCutaneous leishmaniasis patientsCutaneous leishmaniasisFailed treatmentPlasma CmaxTherapeutic responseClinical outcomesPatient's lesionsTreatment outcomesThe different impact of drug-resistant Leishmania on the transcription programs activated in neutrophils
Díaz-Varela M, Sanchez-Hidalgo A, Calderon-Copete S, Tacchini V, Shipley T, Ramírez G, Marquis J, Fernández O, Saravia N, Tacchini-Cottier F. The different impact of drug-resistant Leishmania on the transcription programs activated in neutrophils. IScience 2024, 27: 109773. PMID: 38711445, PMCID: PMC11070714, DOI: 10.1016/j.isci.2024.109773.Peer-Reviewed Original ResearchDrug-resistant parasitesDrug resistanceEffective control of infectionProduction of cytokinesDrug-resistant infectionsControl of infectionMyeloid recruitmentImmune microenvironmentChemokines CCL3Drug susceptibilityMyeloid cellsCCL3 levelsMouse modelNeutrophil subsetsDrug-resistant LeishmaniaNeutrophilsAntimicrobial controlImpaired abilityInfectionCCL3Neutrophil genesTranscriptional programsParasite strainsDrugParasitic diseasesBuilding Research Capacity in Low- and Middle-Income Countries and Pandemic Preparedness: Lessons Learned and Future Directions
Kilmarx P, Goraleski K, Khan E, Lindo J, Saravia N. Building Research Capacity in Low- and Middle-Income Countries and Pandemic Preparedness: Lessons Learned and Future Directions. American Journal Of Tropical Medicine And Hygiene 2024, 110: 417-420. PMID: 38266289, PMCID: PMC10919184, DOI: 10.4269/ajtmh.23-0675.Peer-Reviewed Original ResearchMiddle-income countriesResearch capacityShortage of trained staffLow-and-middle-income countriesBuilding Research CapacityAnd Middle-Income CountriesGlobal Health Security AgendaWorld Health Assembly resolutionPandemic preparednessInterdisciplinary trainingRapid pathogen identificationTask ForceCapacity buildingGlobal initiativesPandemic responseEbola outbreakProactive engagementClinical trialsCollaborative effortsPreparednessGlobal partnershipPathogen identificationDisease researchExperiences of leadersGenome sequence
2023
mHealth Monitoring of Treatment of Cutaneous Leishmaniasis Patients: A Community-Based Implementation Study
Cossio A, Bautista-Gomez M, Alexander N, Del Castillo A, del Mar Castro M, Castaño-Grajales P, Gutiérrez-Poloche Y, Zuluaga L, Vargas-Bernal L, Navarro A, Saravia N. mHealth Monitoring of Treatment of Cutaneous Leishmaniasis Patients: A Community-Based Implementation Study. American Journal Of Tropical Medicine And Hygiene 2023, 109: 778-790. PMID: 37640290, PMCID: PMC10551068, DOI: 10.4269/ajtmh.22-0805.Peer-Reviewed Original ResearchConceptsCommunity health leadersProportion of patientsAdverse drug reactionsCutaneous leishmaniasisDrug reactionsTherapeutic responseHealth workersCutaneous leishmaniasis patientsInitiation of treatmentAnti-leishmanial treatmentStandard of careGlobal health problemMobile health strategiesEffectiveness of treatmentPublic health needsLeishmaniasis patientsCare groupTreatment adherenceHealth strategiesMHealth interventionsPatientsHealth problemsHealth needsMHealth strategiesCase identificationRandomized trial evaluating an mHealth intervention for the early community-based detection and follow-up of cutaneous leishmaniasis in rural Colombia
Castillo M, Alexander N, Rubiano L, Rojas C, Navarro A, Rincon D, Bernal L, Lerma Y, Saravia N, Aronoff-Spencer E. Randomized trial evaluating an mHealth intervention for the early community-based detection and follow-up of cutaneous leishmaniasis in rural Colombia. PLOS Neglected Tropical Diseases 2023, 17: e0011180. PMID: 36972285, PMCID: PMC10079216, DOI: 10.1371/journal.pntd.0011180.Peer-Reviewed Original ResearchConceptsEffectiveness of treatmentIntervention armWeek 26Therapeutic responseCutaneous leishmaniasisHealth systemSerious adverse eventsEnd of treatmentStart of treatmentCutaneous leishmaniasis treatmentProportion of participantsMobile health strategiesPublic health systemCommunity-based detectionTreatment of CLPrimary endpointAdverse eventsMore patientsClinical managementControl armImproved careMedical attentionNational guidelinesParallel armsHealth strategiesCutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study
del Mar Castro M, Rode J, Machado P, Llanos-Cuentas A, Hueb M, Cota G, Rojas I, Orobio Y, Sarmiento O, Rojas E, Quintero J, Pimentel M, Soto J, Suprien C, Alvarez F, Ramos A, dos Santos Arantes R, da Silva R, Arenas C, Vélez I, Lyra M, Saravia N, Arana B, Alexander N. Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study. PLOS Neglected Tropical Diseases 2023, 17: e0011029. PMID: 36689465, PMCID: PMC9894540, DOI: 10.1371/journal.pntd.0011029.Peer-Reviewed Original ResearchConceptsCollaborative retrospective studyRetrospective studyAdverse reactionsCutaneous leishmaniasisAge groupsMedian lesion diameterOverall cure rateOlder adult patientsMost adverse reactionsCutaneous leishmaniasis treatmentYears of ageMonotherapy regimenAdult patientsReferral centerLocal therapyPediatric populationClinical recordsCure rateCL patientsTherapeutic responseClinical trialsDisease presentationMedian numberMild intensityAntileishmanial treatment
2022
Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia
del Mar Castro M, Cossio A, Navas A, Fernandez O, Valderrama L, Cuervo-Pardo L, Marquez-Oñate R, Gómez MA, Saravia NG. Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia. Pathogens 2022, 11: 378. PMID: 35335703, PMCID: PMC8949591, DOI: 10.3390/pathogens11030378.Peer-Reviewed Original ResearchAddition of pentoxifyllinePeripheral blood mononuclear cellsMeglumine antimoniate treatmentPlacebo-controlled trialCutaneous leishmaniasis patientsBlood mononuclear cellsInflammatory gene expressionAntimoniate treatmentOral pentoxifyllineTrial patientsAdverse eventsInflammatory mediatorsMucosal leishmaniasisLeishmaniasis patientsAntimonial treatmentClinical benefitMononuclear cellsStandard treatmentMultiple lesionsTherapeutic failureTherapeutic responseClinical trialsFailure rateStudy groupSingle lesion
2021
Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Ex Vivo Model of Leishmania (Viannia) panamensis Infection
Fernández OL, Rosales-Chilama M, Quintero N, Travi BL, Wetzel DM, Gómez MA, Saravia NG. Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Ex Vivo Model of Leishmania (Viannia) panamensis Infection. Antimicrobial Agents And Chemotherapy 2021, 66: e01425-21. PMID: 34694879, PMCID: PMC8765415, DOI: 10.1128/aac.01425-21.Peer-Reviewed Original ResearchConceptsFractional inhibitory concentration indexPeripheral blood mononuclear cellsL. panamensisHuman peripheral blood mononuclear cellsClinical strainsLeishmania panamensis infectionOral azole drugsOral combination therapyFailure of treatmentBlood mononuclear cellsEfficacy of treatmentNovel therapeutic strategiesEffectiveness of treatmentHigh potencyReduction of infectionEx vivo modelInhibitory concentration indexFree drug concentrationPanamensis infectionPreclinical evidenceCombination therapyMononuclear cellsAntimonial drugsCutaneous leishmaniasisDrug combinations
Academic Achievements & Community Involvement
Get In Touch
Contacts
Academic Office Number